As consumers increasingly hand over their account credentials and credit-card numbers to automatons, Wall Street banks fear their systems will soon be facing off against an army of rogue agents bloomberg.com/news/articles/…
IPODave retweeted
Cboe plans to list options on Anthropic $ANT as soon as Monday, just days after its Thursday Nasdaq debut, with demand potentially exceeding SpaceX's options launch as Anthropic reportedly prices its IPO at $83 a share, valuing it at roughly $1.5T.
IPODave retweeted
JPMORGAN IS TRYING TO SELL $2B OF QUALTRICS DEBT AT A 20% DISCOUNT
JPMorgan is marketing bonds tied to Qualtrics' $6.75B acquisition of Press Ganey Forsta at around 80 cents on the dollar, per FT.
The proposed terms:
• Maturity: 6.5 years
• Coupon: 8%
• Issue price: 80 cents on the dollar
• Implied yield: 12% to 13%
A group of banks, including JPMorgan, has been stuck holding more than $5B of acquisition debt since March after investors pulled back from software financing amid fears that AI could disrupt these businesses.
The banks had committed to providing the financing but couldn't sell the debt to outside investors, forcing them to fund the acquisition themselves.
JPMorgan is now trying to offload part of that debt before year-end, with the new bond sale expected to launch after Thanksgiving. Pricing is not yet final.
Qualtrics' existing term loan maturing in 2030 was also trading at around 82 cents on the dollar on Tuesday.
For comparison, cybersecurity firm Proofpoint just sold $2B of debt, including $1.25B in high-yield bonds that attracted more than $7B in orders and priced at an approximately 8.75% yield.
IPODave retweeted
Everyone is understandably frustrated watching $AAOI file a $550M ATM shelf 12 days after CFO Stefan Murry said on the Q3 call that they planned to rely more on debt and internal cash flow. Management deserves the hit to their credibility for how they telegraphed this.
Once you get past the communication fumble and open the Q3 10-Q, though, the numbers explain what is actually happening behind the scenes:
-The Unfunded Commitments in Note 18: The headline Q3 release showed $621.5M in cash and a new $200M bank loan ($821.5M total liquidity). What most people missed is Note 18 of the 10-Q, which shows $AAOI is carrying $928.8M in binding equipment and facility purchase commitments for Sugar Land Phase 2 and Taiwan. They were already over $100M short of their committed CapEx bill before funding a single dollar of new working capital.
-Funding a $5B+ LTA Without Customer Prepayments: Unlike $LITE, which received upfront customer prepayments to build capacity,$AAOI's first $1B to $1.5B 1.6T contract included zero upfront capital from the hyperscaler. On the Q3 call, Thompson Lin stated a second LTA is in the final stages, weeks away, and at least 5x larger than the first ($5B to $7.5B). Scaling toward $471M/month in revenue by late 2027 means $AAOI has to prepay 1.6T DSP suppliers and front hundreds of millions in inventory and receivables on its own balance sheet while waiting 60 to 90 days for hyperscaler invoices to clear.
-Passing the Counterparty Audit & Selling Into Strength: No Tier 1 hyperscaler risk committee is signing off on a $5B+ contract with a $4B market cap supplier unless that supplier can prove it has the liquidity to survive the working capital ramp. Filing the ATM right after the 10-Q gives $AAOI ~$1.37B in total liquidity capacity to check that box for the customer. It also puts the legal shelf in place now so Raymond James and Needham can quietly sell shares into the massive volume spike after the 5x LTA hits the tape (just like they executed the prior $600M ATM at a $105.36 average price), rather than killing the rally by filing for dilution the day after the announcement.
-The Dilution Runway Through Late 2027: With $1.37B in combined cash, debt, and ATM capacity, the entire $928.8M CapEx commitment is covered with over $440M left for working capital, and Q4 Non-GAAP net income is guided to jump to $46M to $60M in a single quarter. Unless they land yet another massive LTA on top of this upcoming one that requires expanding capacity beyond 1.2M units/month, this should be their last ATM through the end of 2027.
The ATM creates near-term overhead supply and management handled the messaging poorly. Even so, factoring in 10% to 12% dilution and a 50% execution haircut to their late 2027 run rate, $AAOI is trading around 10x buffered 2027 earnings with a $5B+ contract weeks away. Selling in the low $40s right before Q4 earnings inflect misses what this balance sheet is being built to support. I’m holding.
IPODave retweeted
ARK filing for a slew of very specific theme ETFs, which would instantly double their product lineup. It looks like they took their overall strategy and unbundled all of individual themes so people could pick and choose. Could also be looking for way to spark flows, they are -$1b YTD which isnt bad but in year where fish biting so much prob has them looking for new ideas. Only problem is some of these are a bit me-too at this point, AI/tech saturation.
I’ll tell you right now that with $1 trillion in commitments, the Anthropic IPO has been cancelled. Absolutely no bank, pension, or insurer can touch it.
The losses the firms are facing now are enormous and Anthropic is simply bankrupt on its contract terms with companies.
Bond market completely shuts off Anthropic ability to raise debt based on their extreme risk of default. All debt raises will require a parental co-signer for the company. It’s over for Ai.
Anthropic only needs to raise hundreds of billions of dollars a year on other people’s credit history.
TeraWulf signed a credit support agreement with Google $GOOG to support financing for its Justified data center campus in Hawesville, Kentucky, tied to an approximately $19 billion long-term lease commitment with Anthropic.
According to ChainCatcher, Google will provide contractual credit support for anticipated debt financing; Alphabet’s senior unsecured debt is rated AA+ by S&P and Aa2 by Moody’s. The data center is expected to begin phased delivery in late 2027 and continue through the second quarter of 2028. TeraWulf said the agreement strengthens the project’s financing framework and construction execution, helping convert long-term AI and high-performance computing leasing demand into recurring cash flow.
IPODave retweeted
BREAKING: 🇵🇾 What just happened in PARAGUAY is a WARNING for everyone on earth.
More than 3 million people (60% of Paraguay's adult population) have lost access to EVERYTHING. Their bank accounts. Their pensions. Frozen. Inaccessible.
Paraguay’s largest digital bank, Ueno Bank, has collapsed.
The president of the Central Bank (who is deeply connected to Ueno) has just RESIGNED. Eight high-level executives including the founder and the Bank President are being detained.
The people have taken to the streets to demand their money back. And rightly so.
This is the model Milei and the rest of the Epstein class are pushing. This could happen ANYWHERE. Best to save in physical gold and physical silver, imo.
IPODave retweeted
🇮🇹 ITALY IS OFFERING 10 YEARS OF RENT-FREE LIVING.
Calabria has listed 50 homes in 26 villages. The region will fund renovations, and selected residents can live there without paying rent for a decade.
Foreign applicants may qualify.
4 real homes + how to apply 🧵
🤖 Made with AI
IPODave retweeted
Comprehensive list of hedge funds blowing up this week, getting large redemptions, or shutting down PMs:
- Axebrook
- Walleye
- Engineers Gate
- Lone Pine
- Millennium internal pods
- Verition pods
- Samlyn
Letter from Walleye closing internal funds below
IPODave retweeted
How many times can a fund do this ?? Thought they folded earlier this year ?
This quoted post is unavailable.
IPODave retweeted
My take on BP moves:
$jnj : $cogt , $dftx , $ptgx
$lly: $abvx , $mane , $celc , $prax
$mrk: $lqda, $rvmd
$sny: $pcvx , $insm
$abbv: $xene , $prax , $abvx , $vktx
$azn: $cgon , $rytm, $insm, $abvx
$nvs: $cytk , $srrk , $vrdn
$Rhhby: $iron , $vera, $cccc
$pfe: $celc , $cogt , $arct
$bms: $elvn , $cldx
$gsk: $cldx, $amlx , $cccc
$nvo: $gpcr, $ewtx , $rytm
I hope (and think) we are likely to be entering a prime biotech deal-making spree over the next few months.
Pharma valuations have been soaring (and seemingly will continue to do so today), all while quality biotechs that *could* be M&A targets have been relentlessly abused over the last several months.
BTW, side note: If you're looking at the $XBI to determine that "Meh, it hasn't actually been that bad for SMID bios. Look at $XBI in the $150s!!!" - you are absolutely missing the true picture of what has been going on....badly. FORGET the $XBI you think you know - that index is long dead, filled with large cap stocks that DO NOT represent what $XBI used to represent. *And* consider the components that have driven *all* of the upside in the biotech indices of late...it has almost exclusively been GARBAGE that has rallied, leveling out the appearance of damage on the surface, all while under the hood the "quality" stuff has been absolutely demolished.
Let's review the setup for an M&A frenzy here...
➡️Pharma revenues have been looking great. The cash is there, and the confidence in the business is there.
➡️Pharma stock prices are looking even better, despite what has actually been a pretty abysmal series of high-impact clinical trial failures from pharma since around the middle of this year.
➡️The patent cliffs are still there, largely unaddressed. The biggest in history.
➡️Not only that, but the cliffs are actively steepening, because the revenue streams that have (largely) been driving pharma valuations higher and higher are the very ones that are about to run out...making the need to act and fill those impending gaps even more dire (there is MUCH more for a pharma to defend going toward a patent cliff when their stock is +50% YoY - dire loss of revenue streams is simply not being priced in recently...they have to act the make that an actual reality)
➡️The elections are now out of the way and we basically have the guarantee of gridlock for at least 2 more years (healthcare's absolute favorite setup).
➡️Rates/cost of capital are almost certainly coming down as part of last night's election results
➡️The 2 biggest healthcare conferences of the year happen within the next 3 months, and (hopefully) pharma will be eager to keep their momentum going by having comprehensive plans for how they plan to manage their patent cliffs ready to go for investors by JPM...
➡️All the while, "quality" biotech M&A targets have actually been in a legitimate bear market over recent months (again, SPARE ME with references to $XBI - this is a borderline irrelevant datapoint today). This is perhaps the most interesting facet of the setup to me. It seems that absolutely everything points to a near-term resumption in biotech M&A after a several-month drought, yet the M&A targets continue to price in significant skepticism...This *further* incentives deals to happen, as valuations are quite palatable for pharma. Somehow, pharma's desperation can be fully evident WITHOUT the market eroding their bargaining power by bidding up their M&A targets. Really a wonderful setup for deals IMO.
Pharma is flying as high as ever despite many recent clinical-stage setbacks. Gridlock grants them a political tailwind. Their patent cliffs not only draw closer with time, but also steeper with their ever-growing revenues and valuations, which have known expiration dates. All the while, the solution to their problem is no secret: M&A. Yet, the very obvious targets of all these aligning incentives have traded down relentlessly over recent months...Pharma gets the solution to their problems on sale right now despite the fact we all can see they are becoming increasingly mandatory buyers?
Let's hope this is the perfect storm for some serious deal making over the next 3-4 months...the setup certainly looks ripe to me! I predict we will see rapid and *sharp* changes in biotech M&A target valuations as soon as we see a couple decent deals take place...Fingers crossed!
























